Read More Pharma Industry News Can Avacta (AIM: AVCT) sustain momentum as AVA6103 data signals tumor-targeting breakthrough? Avacta shares trade flat after releasing new AVA6103 data. Can the tumor-targeting strategy sustain momentum into Phase 1? Find out what traders expect. byVenkateshDecember 18, 2025